Mythic Therapeutics is pioneering advancements in antibody-drug conjugate (ADC) technology through its innovative FateControl™ platform. This technology enhances the delivery of chemotherapy directly to cancerous cells while minimizing exposure to healthy tissues, which is a significant challenge in traditional ADC therapies. By engineering ADCs to improve their internalization within target cells, Mythic aims to increase the efficacy of treatments across a wider range of cancer types and patient profiles. This approach not only boosts the therapeutic potential of ADCs but also reduces the associated toxicity, leading to better treatment outcomes for patients.

The company's lead candidate, MYTX-011, is specifically designed to target the cMET signaling pathway, which is often overexpressed in various tumors, including non-small cell lung cancer (NSCLC). The ongoing Phase 1 clinical trial, KisMET-01, is evaluating the safety and effectiveness of MYTX-011 in patients with advanced NSCLC. By leveraging the capabilities of the FateControl™ technology, Mythic Therapeutics is working to unlock the full potential of ADCs, aiming to provide effective treatment options for patients who currently have limited therapeutic alternatives. This strategic focus on enhancing ADC performance positions Mythic at the forefront of precision oncology.

United States

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Mythic Therapeutics

Company Details